Vertex’s non-opioid painkiller receives approval from US drug regulator
Vertex Pharmaceuticals Inc.’s non-opioid analgesic to treat moderate to severe acute pain in adults got approval from the US drug regulator.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Vertex Pharmaceuticals Inc.’s non-opioid analgesic to treat moderate to severe acute pain in adults got approval from the US drug regulator.
Britain’s National Health Service will provide a gene therapy that may cure sickle cell disease for patients 12 years and older, according to.
Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its “robust efficacy,” according.
The UNAIDS has welcomed a move by the United States Secretary of State, Marco Rubio, to approve an “Emergency Humanitarian Waiver” to allow.
Eli Lilly has stopped trials of its investigational drug to treat chronic kidney disease for a “lack of foreseeable clinical benefit,” according to.
Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.
Zimmer Biomet Holdings, Inc., a US medical device maker, will acquire Paragon 28 Inc., for $1.1 billion to expand into musculoskeletal care, according.
A US government’s decision to pause funding for HIV programmes in low and middle-income countries will take the world back to the 1980s.
Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug.
Biogen Inc. and its Japanese partner, Eisai Co. Ltd., announced that the US regulator had approved four-weekly maintenance dosing for its Alzheimer's drug.